Search Result

Results for "

MDM-2/p53

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MDM-2/p53 (134) Akt (2) Apoptosis (47) Autophagy (7) Bcl-2 Family (4) Biochemical Assay Reagents (1) Casein Kinase (2) Caspase (8) CDK (1) COX (1) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (1) Cytochrome P450 (2) Deubiquitinase (7) Dihydroorotate Dehydrogenase (1) DNA Methyltransferase (1) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (1) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (34) Ferroptosis (1) Fungal (3) HDAC (2) Herbicide (2) IKZF Family (1) Integrin (1) Interleukin Related (3) Isotope-Labeled Compounds (4) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (1) Lipoxygenase (1) LPL Receptor (1) MAGL (1) NF-κB (2) Parasite (1) PARP (3) PDK-1 (1) PROTACs (8) PTEN (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (4) Reference Standards (4) Sirtuin (1) TNF Receptor (1) Topoisomerase (3) Wnt (1) β-catenin (2)
By Research Areas:	Cancer (141) Cardiovascular Disease (2) Endocrinology (1) Infection (3) Inflammation/Immunology (6) Neurological Disease (7)

By Targets:

MDM-2/p53 (134)

Akt (2)

Apoptosis (47)

Autophagy (7)

Bcl-2 Family (4)

Biochemical Assay Reagents (1)

Casein Kinase (2)

Caspase (8)

CDK (1)

COX (1)

Cyclin G-associated Kinase (GAK) (1)

Cyclophilin (1)

Cytochrome P450 (2)

Deubiquitinase (7)

Dihydroorotate Dehydrogenase (1)

DNA Methyltransferase (1)

Drug Derivative (1)

Drug Intermediate (1)

Drug Isomer (1)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (34)

Ferroptosis (1)

Fungal (3)

HDAC (2)

Herbicide (2)

IKZF Family (1)

Integrin (1)

Interleukin Related (3)

Isotope-Labeled Compounds (4)

Ligands for E3 Ligase (2)

Ligands for Target Protein for PROTAC (1)

Lipoxygenase (1)

LPL Receptor (1)

MAGL (1)

NF-κB (2)

Parasite (1)

PARP (3)

PDK-1 (1)

PROTACs (8)

PTEN (1)

Pyroptosis (1)

Reactive Oxygen Species (ROS) (4)

Reference Standards (4)

Sirtuin (1)

TNF Receptor (1)

Topoisomerase (3)

Wnt (1)

β-catenin (2)

By Research Areas:

Cancer (141)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (6)

Neurological Disease (7)

147

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: MDM-2/p53

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50696

Nutlin-3 40+ Cited Publications	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Nutlin-3 is a commercial available *p53-MDM2* inhibitor, with K_i of 90 nM.

HY-10029

Nutlin-3a Maximum Cited Publications 69 Publications Verification Rebemadlin	MDM-2/p53 E1/E2/E3 Enzyme Autophagy Apoptosis	Cancer
Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). Nutlin-3a inhibits *MDM2-p53* interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas ^[2].

HY-152859

Brigimadlin BI 907828	E1/E2/E3 Enzyme MDM-2/p53	Cancer
Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase *MDM-2* inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research ^[2] .

HY-101518

Alrizomadlin 4 Publications Verification APG-115; AA-115	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Alrizomadlin (APG-115) is an orally active *MDM2* protein inhibitor binding to MDM2 protein with IC₅₀ and K_i values of 3.8 nM and 1 nM, respectively . Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner ^[2] .

HY-10959

RG7112 20+ Cited Publications RO5045337	MDM-2/p53 E1/E2/E3 Enzyme	Neurological Disease Cancer
RG7112 is a potent, selective, orally active and blood-brain barrier crossed *MDM2-p53* inhibitor, with an IC₅₀ of 18 nM and a K_D of 11 nM for binding to MDM2 .

HY-12296

Navtemadlin 25+ Cited Publications AMG 232; KRT-232	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of *p53-MDM2* interaction, with an IC₅₀ of 0.6 nM. Navtemadlin binds to MDM2 with a K_d of 0.045 nM ^[2].

HY-170451

Seldegamadlin 1 Publications Verification KT-253	PROTACs MDM-2/p53 Apoptosis	Cancer
Seldegamadlin (KT-253) is a selective *p53* stabilizer and a MDM2 PROTAC degrader (DC₅₀ = 0.4 nM). Seldegamadlin inhibits the proliferation of cancer cell RS4;11 with an IC₅₀ of 0.3 nM, arrests the cell cycle at G2/M phase, and induces apoptosis. Seldegamadlin upregulates p53 activity and overcomes the p53-MDM2 feedback loop. Seldegamadlin can be used for the study of hematologic and solid tumors, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) ^[2] .

HY-18658

Siremadlin 10+ Cited Publications NVP-HDM201; HDM201	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Siremadlin (NVP-HDM201) is a potent, orally bioavailable and highly specific *p53-MDM2* interaction inhibitor.

HY-18986

SAR405838 3 Publications Verification MI-77301	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity ^[2].

HY-P4210

Sulanemadlin 2 Publications Verification ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-70027A

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor dihydrochloride (Compound 32) is an inhibitor of the interaction between *p53* and *MDM2. p53* and MDM2 proteins-interaction-inhibitor dihydrochloride has potential applications in cancer research .

HY-19726

NSC59984 2 Publications Verification	MDM-2/p53	Cancer
NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway . NSC59984 acts by targeting GOF-mutant p53 and stimulates p73 to restore the p53 pathway signaling ^[2].

HY-176083

ASTX295	MDM-2/p53 Caspase Apoptosis	Cancer
ASTX295 is an orally active and selective *MDM2* antagonist with an IC₅₀ of <1 nM. ASTX295 inhibits the *MDM2-p53* interaction, activates wild-type *TP53, and thereby induces the expression of relevant transcriptional targets, leading to cell death. ASTX295 drives the transition of pancreatic cancer cells from senescence to apoptosis* and regulates *p53* and DNA damage biomarkers. ASTX295 can be used for the research of hematologic malignancies and pancreatic cancer ^[2].

HY-17493

MI-773 5+ Cited Publications	MDM-2/p53 Apoptosis	Neurological Disease Cancer
MI-773 is an orally active, selective *MDM2-p53* interaction inhibitor with a K_i of 0.88 nM for MDM2. MI-773 blocks the *MDM2*-TP53 interaction. MI-773 potently activates *p53. MI-773 induces Apoptosis*. MI-773 causes tumor regression in xenograft models of adenoid cystic carcinoma. MI-773 exhibits anticancer effects in neuroblastoma. MI-773 TFA can be used for the research of adenoid cystic carcinoma ^[2].

HY-13423

Tenovin-1 5 Publications Verification	MDM-2/p53 Dihydroorotate Dehydrogenase Sirtuin Autophagy	Cancer
Tenovin-1, a *p53* activator, protects p53 from MDM2-mediated degradation. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also a dihydroorotate dehydrogenase (DHODH) inhibitor ^[2].

HY-128841

PROTAC MDM2 Degrader-2 1 Publications Verification	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-2 is an MDM2 PROTAC degrader. PROTAC MDM2 Degrader-2 can induce the self-ubiquitination and degradation of *MDM2, thereby upregulating the level of p53* protein. PROTAC MDM2 Degrader-2 has anti-tumor activity and can be used in the study of cancer .

HY-153215

MEL24	Ligands for E3 Ligase	Cancer
MEL24 is an Mdm2 E3 ligase inhibitor that reduces cell survival and increases sensitivity to DNA damaging agents in a p53-dependent manner for in vitro antitumor studies .

HY-158684

YX-02-030	PROTACs MDM-2/p53 Apoptosis	Cancer
YX-02-030 is a VHL-dependent *MDM2* PROTAC degrader with a K_d of 35 nM. YX-02-030 recruits the VHL E3 ligase to form a ternary complex, leading to ubiquitination and proteasome-mediated degradation of MDM2. YX-02-030 inhibits MDM2-p53 and VHL-HIF1α binding with IC₅₀ values of 63 and 1350 nM. YX-02-030 activates TAp73, upregulates *p53* family target genes and induces apoptosis. YX-02-030 demonstrates on-target efficacy in TNBC xenograft-bearing mice, extending survival without normal cell toxicity .

HY-120086

RO-5963 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
RO-5963 is a dual *p53-MDM2* and *p53-MDMX* inhibitor with IC₅₀s of ~17 nM and ~24 nM, respectively .

HY-70027

p53 and MDM2 proteins-interaction-inhibitor (chiral)	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 protein-interaction inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between *p53* and *MDM2. p53* and MDM2 protein-interaction inhibitor (chiral) has potential applications in cancer research .

HY-125858

MI-1061 3 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
MI-1061 is a potent, orally bioavailable, and chemically stable *MDM2* (MDM2-p53 interaction) inhibitor (IC₅₀=4.4 nM; K_i=0.16 nM). MI-1061 potently activates *p53* and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .

HY-141584

ATSP-7041	MDM-2/p53	Cancer
ATSP-7041, a selective dual peptide inhibitor of *MDM2* and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .

HY-16999

RO8994	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
RO8994 (Compound 4) is an orally active, highly potent and selective spiroindolinone *p53-MDM2* inhibitor with an IC₅₀ value of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays). RO8994 induces up-regulation of *p53* expression and Apoptosis in wild-type p53 cancer cells. RO8994 also inhibits tumor growth in the tumor xenograft model ^[2] .

HY-120084

BTX161 1 Publications Verification	Casein Kinase	Cancer
BTX161, a thalidomide analog, is an effective CKIα degrader. BTX161 mediates human AML cell CKIα degradation more effectively than lenalidomide and activates the DNA damage response (DDR) and p53, while stabilizing p53 antagonist MDM2.

HY-148833

MDM2-p53-IN-16	MDM-2/p53	Cancer
MDM2-p53-IN-16 is a *MDM2-p53* complex inhibitor with an IC₅₀ value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .

HY-P1755

p53 (17-26)	MDM-2/p53	Cancer
p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a K_d of 50 nM for *MDM2. p53* (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer ^[2].

HY-169240

MX69-102	MDM-2/p53	Cancer
MX69-102 (compound MX69-102) is an *MDM-2/p53* inhibitor, inducing *MDM2* degradation, resulting in *p53* activation and cancer cell apoptosis. MX69-102 shows effective inhibition on xenografted human MDM2-overexpressing ALL in SCID mice. .

HY-W340313

p53-MDM2-IN-4	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-4 (Example 4) is an inhibitor of *p53-MDM2/X* protein interaction, with a K_i value of 3.079 μM. p53-MDM2-IN-4 can be used in anti-tumor research .

HY-W340839

p53-MDM2-IN-1	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-1 (Example 30) is an inhibitor of *p53-MDM2/X* protein interaction with an K_i value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .

HY-15676A

Idasanutlin (enantiomer) RG7388 (enantiomer)	MDM-2/p53 Drug Isomer Apoptosis	Cancer
Idasanutlin enantiomer is the isomer of Idasanutlin (HY-15676), and can be used as an experimental control. Idasanutlin (RG7388) is a potent and selective *MDM2* antagonist, inhibiting p53-MDM2 binding, with an IC₅₀ of 6 nM.

HY-128840

PROTAC MDM2 Degrader-1	PROTACs MDM-2/p53	Cancer
PROTAC MDM2 Degrader-1 (Compound 15a) is a MDM2 PROTAC degrader. The structures of both Linker ends of PROTAC MDM2 Degrader-1 are MDM2 ligands. PROTAC MDM2 Degrader-1 can not only block the binding of p53-MDM2, but also degrade the target MDM2 protein by utilizing the function of the E3 ligase of MDM2 itself, thus exerting an anti-tumor effect .

HY-76667

3-(Boc-amino)propyl bromide	MDM-2/p53 Biochemical Assay Reagents Drug Intermediate	Others
3-(Boc-amino) propyl bromide is an alkylating reagent used for the N-alkylation of benzopyranotriazolopyrimidine-based *MDM2-p53* protein-protein inhibitor 4 to prepare Compound 13 .

HY-148106

MEL23	Ligands for E3 Ligase	Cancer
MEL23 is a MDM2 E3 ligase inhibitor that blocks the E3 ligase activity of the MDM2-MDMX complex. MEL23 inhibits Mdm2 and p53 ubiquitination in cells, reduce viability of cells with wild-type p53. MEL23 stabilizes MDM2 via a mechanism independent of p53 transcription .

HY-P1755F

p53 (17-26), FITC labeled	MDM-2/p53	Cancer
p53 (17-26), FITC labeled is a biological active peptide. p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a K_d of 50 nM for *MDM2. p53* (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer.

HY-123950

MMRi64	MDM-2/p53 Apoptosis	Cancer
MMRi64 disrupts *Mdm2-MdmX* interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces *p53* accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research .

HY-70028

p53 and MDM2 proteins-interaction-inhibitor (racemic)	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor (racemic) (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-100765

BI-0252	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
BI-0252 is an orally active, selective *MDM2-p53* inhibitor with an IC₅₀ of 4 nM. BI-0252 can induce tumor regressions in all animals of a mouse SJSA-1 xenograft, with concomitant induction of the tumor protein p53 (TP53) target genes and markers of apoptosis .

HY-14967

NSC 66811 1 Publications Verification	MDM-2/p53	Cancer
NSC 66811 is a *MDM2-p53* inhibitor, with a K_i of 120 nM for binding to MDM2 .

HY-158685

RG7112D	MDM-2/p53	Cancer
RG7112D is a potent *MDM2* inhibitor with IC₅₀s of 11 nM and >10000 nM and for MDM2-p53 and VHL-HIF1α by binding HTRF assay, respectively. RG7112D is coupled by an amide bond to VHL-Amine, resulting in a bi-functional molecule, YX-02-030. YX-02-03, a MDM2-PROTAC, potently inhibits MDM2-p53 binding (HTRF IC₅₀=63nM). RG7112D can stabilize MDM2 protein and increase p53 protein levels .

HY-124791

MMRi6	MDM-2/p53 PARP	Cancer
MMRi6 is a Mdm2-MdmX RING domain inhibitor that can disrupt Mdm2-MdmX RING-RING interaction in vitro. MMRi6 inhibits MdmX-stimulated *Mdm2* autoubiquitination and Mdm2-MdmX-mediated *p53* polyubiquitination in vitro without affecting NEDD4-1 autoubiquitination. MMRi6 induces *p53* stabilization and accumulation and induces PARP cleavage in wt-p53 Emu-myc lymphoma cells. MMRi6 inhibits the growth of wt-p53 and *p53*-null Emu-myc lymphoma cells with IC₅₀s of approximately 0.5 μM and 3 μM, respectively. MMRi6 can be used for the study of leukemia/lymphoma .

HY-P1755A

p53 (17-26) acetate	MDM-2/p53	Cancer
p53 (17-26) acetate is a peptide derived from the P53 MDM2 binding domain, with a K_d of 50 nM for *MDM2. p53* (17-26) acetate causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) acetate exhibits antitumor activity and is applicable to research related to pancreatic cancer ^[2].

HY-P11256

pDI	MDM-2/p53	Cancer
pDI is a peptide. pDI inhibits *MDM2-p53* and *MDMX-p53* interactions with IC₅₀s of 10 and 100 nM respectively. pDI can be used in the research of colorectal cancer .

HY-149988

UNP-6457	MDM-2/p53	Cancer
UNP-6457 is a potent active *MDM2-p53* interaction inhibitor with an IC₅₀ values of 8.9 nM .

HY-12287

YH239-EE 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent.

HY-133760

MI-888	MDM-2/p53	Cancer
MI-888 is an orally active *MDM2* inhibitor with a K_i of 0.44 nM. MI-888 can inhibit the *MDM2-p53* interaction. MI-888 has favorable pharmacokinetic properties and anti-tumor activity .

HY-10029A

(Rac)-Nutlin-3 (Rac)-Rebemadlin	MDM-2/p53 Autophagy Apoptosis E1/E2/E3 Enzyme	Cancer
(Rac)-Nutlin-3 (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). (Rac)-Nutlin-3 inhibits *MDM2-p53* interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. (Rac)-Nutlin-3 has the potential for the study of TP53 wild-type ovarian carcinomas ^[2].

HY-169327

MD-265	PROTACs MDM-2/p53	Cancer
MD-265 is a PROTAC degrader that can break down *MDM2, leading to activation of p53* in cancer cells carrying wild-type p53. MD-265 achieves complete tumor regression and improves long-term survival of mice with leukemia .

HY-163661

p53-MDM2-IN-5	Apoptosis Autophagy MDM-2/p53	Cancer
p53-MDM2-IN-5 (compound 5a) is a potent *p53-MDM2* inhibitor. p53-MDM2-IN-5 induces apoptosis, autophagy and DNA damage. p53-MDM2-IN-5 induces cell cycle arrest at S and G2/M phases. p53-MDM2-IN-5 shows anti-tumor activity .

HY-151172

MDM2-p53-IN-15	MDM-2/p53 Apoptosis	Cancer
MDM2-p53-IN-15 is a *MDM2-p53* inhibitor with an IC₅₀ value of 26.1 nM. MDM2-p53-IN-15 inhibits the proliferation of various cancer cells and induces cell apoptosis. MDM2-p53-IN-15 can be used for the research of cancer .

HY-162927

p53-MDM2-IN-6	MDM-2/p53 Apoptosis	Cancer
p53-MDM2-IN-6 (Compound 10a), a LSM-83177 hydrazone analog, is a potent *p53-MDM2* inhibitor with an IC₅₀ value of 11.08 µg/mL. p53-MDM2-IN-6 arrests the cell cycle in the S phase and induces early and late Apoptosis with antiproliferative activity against HT29 cell lines with an IC₅₀ value of 10.44 µg/mL. p53-MDM2-IN-6 inhibits p53-MDM2 interaction with increment in p-53 level and decrease the expression of GST enzymes. p53-MDM2-IN-6 is promising for research of colorectal cancer .

Cat. No.	Product Name

HY-L003

Apoptosis Compound Library

3,464 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 3,464 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

HY-L109

Protein-protein Interaction Inhibitor Library

797 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 797 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-P4210

Sulanemadlin 2 Publications Verification ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-P3509

PNC-28	MDM-2/p53	Cancer
PNC-28 is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 can be used for pancreatic cancer research ^[2].

HY-141584

ATSP-7041	MDM-2/p53	Cancer
ATSP-7041, a selective dual peptide inhibitor of *MDM2* and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .

HY-P1755

p53 (17-26)	MDM-2/p53	Cancer
p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a K_d of 50 nM for *MDM2. p53* (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer ^[2].

HY-P3509A

PNC-28 acetate	MDM-2/p53	Cancer
PNC-28 acetate is a peptide from the mdm-2-binding domain (residues 17–26) of the p53 protein which contains a membrane crossing-penetratin sequence. PNC-28 acetate can be used for pancreatic cancer research ^[2].

HY-106263B

Tyroserleutide hydrochloride	PTEN PDK-1 MDM-2/p53 Apoptosis Akt	Cancer
Tyroserleutide hydrochloride is a tripeptide isolated from the degradation products of porcine spleen with antitumor activity. Tyroserleutide hydrochloride can upregulate the expression of the tumor suppressor gene PTEN and inhibit the activity of AKT and PDK1. Tyroserleutide hydrochloride inhibits tumor cell proliferation and MDM2 phosphorylation by inhibiting the PI3K/AKT pathway, and also upregulates P21, P27, P53, and induces mitochondrial damage and cell apoptosis ^[2] .

HY-P1755F

p53 (17-26), FITC labeled	MDM-2/p53	Cancer
p53 (17-26), FITC labeled is a biological active peptide. p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a K_d of 50 nM for *MDM2. p53* (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer.

HY-P1755A

p53 (17-26) acetate	MDM-2/p53	Cancer
p53 (17-26) acetate is a peptide derived from the P53 MDM2 binding domain, with a K_d of 50 nM for *MDM2. p53* (17-26) acetate causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) acetate exhibits antitumor activity and is applicable to research related to pancreatic cancer ^[2].

HY-P11256

pDI	MDM-2/p53	Cancer
pDI is a peptide. pDI inhibits *MDM2-p53* and *MDMX-p53* interactions with IC₅₀s of 10 and 100 nM respectively. pDI can be used in the research of colorectal cancer .

HY-P10286

Phage-derived 12/1 peptide	MDM-2/p53	Cancer
Phage-derived 12/1 peptide exhibits antitumor activity by targeting *MDM2* and MDMX, an thus disrupt the MDM2-p53 and MDMX-p53 interaction, with IC₅₀ of 0.15 and 1.25 μM .

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for *MDM2* and the activator for *p53* signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models ^[2].

HY-P11490

DPMI-ω	MDM-2/p53	Inflammation/Immunology Cancer
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins *MDM2* and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the *p53* signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 ⁺/CD8 ⁺ cytotoxic T cells and suppressing CD4 ⁺/CD25 ⁺ regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0068

Solasodine 5 Publications Verification Purapuridine; Solancarpidine; Solasodin	Cardiovascular Disease Infection Alkaloids Piperidine Alkaloids Classification of Application Fields Neurological Disease Solanum nigrum Linn. Plants Solanaceae Disease Research Fields Inflammation/Immunology Source Classification	MDM-2/p53 Fungal E1/E2/E3 Enzyme Apoptosis
Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine induces apoptosis by inhibiting the p53-MDM2 complex, p21Waf1/Cip1, and Bcl-2 proteins. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities ^[2] .

HY-N7012

7,3',4'-Tri-O-methylluteolin 1 Publications Verification 5-Hydroxy-3',4',7-trimethoxyflavone	Flavonoids Monophenols Classification of Application Fields Flavones Labiatae Phenols Plants Disease Research Fields Swartzia polyphylla DC. Inflammation/Immunology Source Classification	Lipoxygenase TNF Receptor Interleukin Related COX Fungal Parasite Apoptosis
7,3',4'-Tri-O-methylluteolin (5-Hydroxy-3',4',7-trimethoxyflavone) is a flavonoid with multiple biological activities. 7,3',4'-Tri-O-methylluteolin inhibits soybean lipoxygenase (LOX), with an IC₅₀ value of 23.97 µg/mL. 7,3',4'-Tri-O-methylluteolin possesses anti-inflammatory effects in Lipopolysaccharides (HY-D1056) (LPS)-induced RAW 264.7 macrophages. 7,3',4'-Tri-O-methylluteolin inhibits the binding of MDM2 with p53 and induces apoptosis in MCF-7 breast cancer cells. 7,3',4'-Tri-O-methylluteolin also has antioxidant, antifungal and antitrypanosomal activities ^[2] sup>[4]sup>[5].

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701593

	MDM2 Protein, Human MDM2; E3 ubiquitin-protein ligase MDM2; Double minute 2 protein; Hdm2; Oncoprotein MDM2; RING-type E3 ubiquitin transferase MDM2; p53-binding protein MDM2	Human	E. coli
	MDM2 protein is a key E3 ubiquitin protein ligase that coordinates cellular processes by ubiquitinating and degrading p53/TP53 and inhibiting its tumor suppressor function. In addition to p53/TP53 regulation, MDM2 inhibits p53/TP53- and p73/TP73-mediated responses, self-ubiquitinates, and targets ARRB1 for degradation. MDM2 Protein, Human is the recombinant human-derived MDM2 protein, expressed by E. coli , with tag free.

HY-P701594

	MDM2 Protein, Human (His) MDM2; E3 ubiquitin-protein ligase MDM2; Double minute 2 protein; Hdm2; Oncoprotein MDM2; RING-type E3 ubiquitin transferase MDM2; p53-binding protein MDM2	Human	E. coli
	MDM2 protein is a key E3 ubiquitin protein ligase that coordinates cellular processes by ubiquitinating and degrading p53/TP53 and inhibiting its tumor suppressor function. In addition to p53/TP53 regulation, MDM2 inhibits p53/TP53- and p73/TP73-mediated responses, self-ubiquitinates, and targets ARRB1 for degradation. MDM2 Protein, Human (His) is the recombinant human-derived MDM2 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-153939S

Idasanutlin-d3-1
Idasanutlin-d₃-1 (RG7388-d₃-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of *MDM2/p53*. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia ^[2].

HY-W704348

Diphenyltin Dichloride-d10
Diphenyltin Dichloride-d₁₀ is the deuterium labeled NSC405640 (HY-144105). NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .

HY-12296S

Navtemadlin-d7
Navtemadlin-d₇ is the deuterium labeled Navtemadlin. Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC₅₀ of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM ^[2].

HY-18986S

SAR405838-d10
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity ^[2] .

Host:	Mouse (3) Rabbit (1)
Reactivity:	Human (4) Rat (1) Mouse (1) Monkey (1)
Application:	IHC-P (4) ICC/IF (2) IP (1) WB (4) FC (2) ELISA (3)
Isotype:	IgG (1) IgG1 (3)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (3) Recombinant (1)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83705

	MDM2 Antibody (YA3442) ACTFS antibody; Double minute 2 protein antibody; E3 ubiquitin-protein ligase MDM2 antibody; Hdm 2 antibody; Hdm2 antibody; HDMX antibody; MDM 2 antibody; MDM2 antibody; MDM2 oncogene E3 ubiquitin protein ligase antibody; MDM2 p53 E3 ubiquitin protein ligase homolog antibody; MDM2 transformed 3T3 cell double minute 2 p53 binding protein (mouse) binding protein 104kDa antibody; MDM2_HUMAN antibody; MDM2BP antibody; Mouse Double Minute 2 antibody; MTBP antibody; Murine Double Minute Chromosome 2 antibody; Oncoprotein MDM2 antibody; p53 Binding Protein MDM2 antibody; p53-binding protein MDM2 antibody; Ubiquitin protein ligase E3 MDM2 antibody; Ubiquitin protein ligase E3 MDM2 antibody	WB, IHC-P, ICC/IF	Human, Monkey
	MDM2 Antibody (YA3442) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to MDM2.

HY-P86219

	MDM2 Antibody (YA5911) MDM2; E3 ubiquitin-protein ligase MDM2; Double minute 2 protein; Hdm2; Oncoprotein MDM2; p53-binding protein MDM2	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	MDM2 Antibody (YA5911) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MDM2.

HY-P85272

	MDMX Antibody (YA4964) MDM4; MDMX; Protein MDM4; Double minute 4 protein; MDM2-like p53-binding protein; Protein MDMx; p53-binding protein MDM4	WB, IHC-P, FC, ELISA	Human
	MDMX Antibody (YA4964) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to MDMX.

HY-P85272A

	MDMX Antibody (YA4964)(PBS only) MDM4; MDMX; Protein MDM4; Double minute 4 protein; MDM2-like p53-binding protein; Protein MDMx; p53-binding protein MDM4	WB, IHC-P, FC, ELISA	Human
	MDMX Antibody (YA4964) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to MDMX.